摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-chlorophenyl)-4-methyl-1H-benzimidazole | 75134-08-6

中文名称
——
中文别名
——
英文名称
2-(4-chlorophenyl)-4-methyl-1H-benzimidazole
英文别名
2-(4'-Chlorophenyl)-7-methyl-1H-benzo[d]imidazole (27)
2-(4-chlorophenyl)-4-methyl-1H-benzimidazole化学式
CAS
75134-08-6
化学式
C14H11ClN2
mdl
MFCD11849230
分子量
242.708
InChiKey
MGOIQZBDRJPFOA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    431.2±47.0 °C(Predicted)
  • 密度:
    1.286±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.071
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为产物:
    描述:
    硼酸甘油 作用下, 以 为溶剂, 生成 2-(4-chlorophenyl)-4-methyl-1H-benzimidazole
    参考文献:
    名称:
    硼酸和甘油的水介导合成2-取代的苯并咪唑
    摘要:
    已开发出一种非常简单,温和且高效的绿色催化剂,用于在硼酸(5摩尔%)和80℃的存在下于80°C的水中处理取代的邻苯二胺和醛来合成2-取代的苯并咪唑。甘油(0.05 mL)。该方法已在55种底物上标准化,并合成了9种新化合物。
    DOI:
    10.1071/ch08309
点击查看最新优质反应信息

文献信息

  • Additive- and Oxidant-Free Expedient Synthesis of Benzimidazoles Catalyzed by Cobalt Nanocomposites on N-Doped Carbon
    作者:Zhaozhan Wang、Tao Song、Yong Yang
    DOI:10.1055/s-0037-1610353
    日期:2019.2
    phenylenediamines and aldehydes catalyzed by a highly recyclable nonnoble cobalt nanocomposite was developed. A broad set of benzimidazoles can be efficiently synthesized in high yields and with good functional-group tolerance under additive- and oxidant-free mild conditions. The catalyst can be easily recycled for successive uses, and the process permits gram-scale syntheses of benzimidazoles.
    通过高度可回收的非贵金属钴纳米复合材料催化苯二胺和醛的偶联,开发了一种一锅法直接合成广泛的生物活性苯并咪唑。在无添加剂和无氧化剂的温和条件下,可以以高产率有效合成一系列苯并咪唑,并具有良好的官能团耐受性。该催化剂可以很容易地循环使用以供后续使用,并且该方法允许进行克级规模的苯并咪唑合成。
  • Synthesis, α-glucosidase inhibitory, cytotoxicity and docking studies of 2-aryl-7-methylbenzimidazoles
    作者:Muhammad Taha、Nor Hadiani Ismail、Syahrul Imran、Muhammad Helmi Mohamad、Abdul Wadood、Fazal Rahim、Syed Muhammad Saad、Ashfaq ur Rehman、Khalid Mohammed Khan
    DOI:10.1016/j.bioorg.2016.02.004
    日期:2016.4
    Benzimidazole analogs 1-27 were synthesized, characterized by EI-MS and H-1 NMR and their alpha-glucosidase inhibitory activities were found out experimentally. Compound 25, 19, 10 and 20 have best inhibitory activities with IC50 values 5.30 +/- 0.10, 16.10 +/- 0.10, 25.36 +/- 0.14 and 29.75 +/- 0.19 respectively against alpha-glucosidase. Compound 6 and 12 has no inhibitory activity against alpha-glucosidase enzyme among the series. Further studies showed that the compounds are not showing any cytotoxicity effect. The docking studies of the compounds as well as the experimental activities of the compounds correlated well. From the molecular docking studies, it was observed that the top ranked conformation of all the compounds fit well in the active site of the homology model of alpha-glucosidase. (C) 2016 Elsevier Inc. All rights reserved.
  • γ-Maghemite-silica nanocomposite: A green catalyst for diverse aromatic N-heterocycles
    作者:Pranab Ghosh、Amitava Mandal、Raju Subba
    DOI:10.1016/j.catcom.2013.06.026
    日期:2013.11
    gamma-Maghemite-silica nanocomposite has been applied as a green catalyst to synthesize variety of aromatic N-heterocycles under solvent free conditions. Characterization was done by modern analytical tools (UV, IR, AAS, DSC, EDXRF, powdered XRD, EPR, Mossbauer and TEM). Mild reaction conditions and recyclability have made the present protocol both environmentally and economically viable. (c) 2013 Elsevier B.V. All rights reserved.
  • BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS
    申请人:Wilson Dean M.
    公开号:US20080306129A1
    公开(公告)日:2008-12-11
    The present invention relates to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the R 1 , Z, Y, R A , and W groups of formula I are as defined herein. The invention also provides pharmaceutically acceptable compositions and methods of using the compositions in the treatment of various disorders.
  • US7309716B2
    申请人:——
    公开号:US7309716B2
    公开(公告)日:2007-12-18
查看更多